Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U I Schwarz

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
European Journal of Clinical Investigation|December 4, 2003
Clinical relevance of genetic polymorphisms in the human CYP2C9 geneU I Schwarz
International Journal of Clinical Pharmacology and Therapeutics|April 28, 2000
P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humansU I Schwarz, T Gramatté, J Krappweis, et al.
Deutsche Medizinische Wochenschrift (1946)|July 27, 2004
[Epidemiology of attempted suicide using drugs. An inquiry from the Dresden University Clinic]U I Schwarz, S Rüder, J Krappweis, et al.
Clinical Therapeutics|July 13, 2000
Outpatient costs of osteoporosis in a national health insurance populationJ Krappweis, A Rentsch, U I Schwarz, et al.
International Journal of Clinical Pharmacology and Therapeutics|July 8, 1999
Regional drug information serviceU I Schwarz, S Stoelben, U Ebert, et al.
Archives of Disease in Childhood|July 18, 2009
Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1S Sakaguchi, F Garcia-Bournissen, R Kim, et al.
Clinical Pharmacology and Therapeutics|March 30, 1999
Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humansU I Schwarz, T Gramatté, J Krappweis, et al.
Journal of Population Therapeutics and Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharmacologie Clinique|March 8, 2016
Genetic Predictors of Azathioprine Toxicity and Clinical Response in Patients with Inflammatory Bowel DiseaseB Al-Judaibi, U I Schwarz, N Huda, et al.
Clinical Pharmacology and Therapeutics|March 30, 2007
Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinololU I Schwarz, H Hanso, R Oertel, et al.
Molecular Pharmacology|July 17, 2001
Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African AmericansL J Dickmann, A E Rettie, M B Kneller, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
European Journal of Clinical Investigation|December 4, 2003
Clinical relevance of genetic polymorphisms in the human CYP2C9 geneU I Schwarz
International Journal of Clinical Pharmacology and Therapeutics|April 28, 2000
P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humansU I Schwarz, T Gramatté, J Krappweis, et al.
Deutsche Medizinische Wochenschrift (1946)|July 27, 2004
[Epidemiology of attempted suicide using drugs. An inquiry from the Dresden University Clinic]U I Schwarz, S Rüder, J Krappweis, et al.
Clinical Therapeutics|July 13, 2000
Outpatient costs of osteoporosis in a national health insurance populationJ Krappweis, A Rentsch, U I Schwarz, et al.
International Journal of Clinical Pharmacology and Therapeutics|July 8, 1999
Regional drug information serviceU I Schwarz, S Stoelben, U Ebert, et al.
Archives of Disease in Childhood|July 18, 2009
Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1S Sakaguchi, F Garcia-Bournissen, R Kim, et al.
Clinical Pharmacology and Therapeutics|March 30, 1999
Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humansU I Schwarz, T Gramatté, J Krappweis, et al.
Journal of Population Therapeutics and Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharmacologie Clinique|March 8, 2016
Genetic Predictors of Azathioprine Toxicity and Clinical Response in Patients with Inflammatory Bowel DiseaseB Al-Judaibi, U I Schwarz, N Huda, et al.
Clinical Pharmacology and Therapeutics|March 30, 2007
Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinololU I Schwarz, H Hanso, R Oertel, et al.
Molecular Pharmacology|July 17, 2001
Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African AmericansL J Dickmann, A E Rettie, M B Kneller, et al.
Pageof 2